ECG abnormalities associated with increased cardiovascular disease risk in REGARDS cohort analysis
Can a simple heart test spot hidden risk in people considered low risk?
A prospective cohort analysis of 19,173 participants without baseline CVD found ECG abnormalities were associated with incident CVD events. …
A routine heart test can spot hidden risks in people considered low risk, as those with major ECG abnormalities faced a 53% higher chance of…
Preliminary U.S. data links underlying health conditions to higher COVID-19 severity risk
Early U.S. data suggests certain health conditions may increase severe COVID-19 risk.
A preliminary U.S. observational report suggests patients with COVID-19 who have underlying conditions like diabetes, cardiovascular disease…
Early U.S. data suggests people with diabetes, heart disease, lung issues, or who smoke face higher risk for severe COVID-19 requiring hospi…
Report examines cardiovascular health and predicted heart age in US cancer survivors
Researchers examine cardiovascular health and heart age in US cancer survivors
An observational report describes cardiovascular health and predicted heart age in cancer survivors in the United States. No specific study …
A new report examines predicted heart age among US cancer survivors to understand their cardiovascular health challenges.
Metabolic syndrome associated with higher cardio-renal risk in kidney transplant recipients
Metabolic syndrome linked to higher risks for heart problems and kidney graft issues after transplant
A meta-analysis of 8,986 kidney transplant recipients found metabolic syndrome was associated with higher risks of major adverse cardiovascu…
Kidney transplant patients with metabolic syndrome face double the risk of major heart events and higher chances of graft failure or death.
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…